Citation Impact
Citing Papers
The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate
2009
Cost-Effectiveness of Vertebral Fracture Assessment to Detect Prevalent Vertebral Deformity and Select Postmenopausal Women With a Femoral Neck T-Score > −2.5 for Alendronate Therapy: A Modeling Study
2006
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
2009 Standout
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
2010
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2012 Standout
FRAX™ and the assessment of fracture probability in men and women from the UK
2008 Standout
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2008
Clinician’s Guide to Prevention and Treatment of Osteoporosis
2014 Standout
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary
2016
Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density<SUBTITLE>The Women's Health Initiative Randomized Trial</SUBTITLE>
2003 Standout
Vertebral Fractures
2011
Osteoporosis
2019 Standout
Bazedoxifene for the prevention of postmenopausal osteoporosis
2008
Osteoporosis
2006
Alzheimer Mechanisms and Therapeutic Strategies
2012
Treatment Strategies Targeting Amyloid -Protein
2012
Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
2008
The glymphatic pathway in neurological disorders
2018 Standout
Emerging therapeutic opportunities for skeletal restoration
2011
Vertebral Fracture Assessment: The 2005 ISCD Official Positions
2006
Guidance for the adjustment of FRAX according to the dose of glucocorticoids
2011
Why are some STEM fields more gender balanced than others?
2016 Standout
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide
2005
The use of parathyroid hormone in the treatment of osteoporosis
2006
Bone Quality — The Material and Structural Basis of Bone Strength and Fragility
2006 Standout
Osteoporosis: now and the future
2011 Standout
FRAX® with and without Bone Mineral Density
2011
CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study
2013
Alzheimer disease therapy—moving from amyloid-β to tau
2013
Parathyroid Hormone as an Anabolic Skeletal Therapy
2005
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
2015 Standout
Skeletal remodeling in health and disease
2007 Standout
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Immune attack: the role of inflammation in Alzheimer disease
2015 Standout
WNT signaling in bone homeostasis and disease: from human mutations to treatments
2013 Standout
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
2019 Standout
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
2019
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
2010
PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase‐3β in osteoblastic Saos‐2 cells
2007 StandoutNobel
Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
2014
A systematic review of diagnostic accuracy of vertebral fracture assessment (VFA) in postmenopausal women and elderly men
2016
Current options for the management of postmenopausal osteoporosis
2011
The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women
2007
Tau-aggregation inhibitor therapy for Alzheimer's disease
2013
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis
2011
The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years
2011
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Alzheimer's disease
2016 Standout
Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis
2013 StandoutNobel
Epidemiology of Vertebral Fractures
2015
Resolution of Bisphosphonate-Associated Osteonecrosis of the Mandible: Possible Application for Intermittent Low-Dose Parathyroid Hormone [rhPTH(1-34)]
2007
Primary hyperparathyroidism and the skeleton
2008
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Interpretation and use of FRAX in clinical practice
2011
The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
2018
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
2014
Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 1: Hip Geometry
2015
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Drug Insight: breast cancer prevention and tissue-targeted hormone replacement therapy
2007
Design of amyloidogenic peptide traps
2024 StandoutNobel
A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®
2010
Management of severe osteoporosis
2015
Periosteum: biology, regulation, and response to osteoporosis therapies
2004
Osteoporosis-pseudoglioma syndrome: Description of 9 new cases and beneficial response to bisphosphonates
2008
Osteoporosis: burden, health care provision and opportunities in the EU
2011
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
2005
Intrarater Reliability of Dual-Energy X-Ray Absorptiometry–Based Measures of Vertebral Height in Postmenopausal Women
2012
Protein therapeutics: a summary and pharmacological classification
2007 Standout
The amyloid state and its association with protein misfolding diseases
2014 Standout
Chronic Kidney Disease
2016 Standout
Mechanisms of Anabolic Therapies for Osteoporosis
2007
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club
2005
The amyloid hypothesis of Alzheimer's disease at 25 years
2016 Standout
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
2016
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Theoretical Implications of the Biomechanical Fracture Threshold
2008
Current and Future Treatments in Alzheimer Disease: An Update
2020
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective
2008
Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review for the U.S. Preventive Services Task Force
2013
Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study
2005
Is there Any Interest in Combining Treatments in Osteoporosis?
2005
Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration
2021 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study
2005
Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee
2012 Standout
A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short-Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide
2006
Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: Results from the EUROFORS study
2009
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
2016 Standout
Anabolic and Catabolic Regimens of Human Parathyroid Hormone 1–34 Elicit Bone- and Envelope-Specific Attenuation of Skeletal Effects in Sost-Deficient Mice
2011
Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis
2007
Screening for Osteoporosis: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation
2010
Interrater reliability: the kappa statistic.
2012 Standout
A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules
2015 Standout
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
2008
Relationship Between Changes in BMD and Nonvertebral Fracture Incidence Associated With Risedronate: Reduction in Risk of Nonvertebral Fracture Is Not Related to Change in BMD
2005
Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
2005
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
2005 Standout
Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis
2005
Emerging drugs for postmenopausal osteoporosis
2009
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX
2012
In Vivo Magnetic Resonance Detects Rapid Remodeling Changes in the Topology of the Trabecular Bone Network After Menopause and the Protective Effect of Estradiol
2008
β-Arrestin-biased ligands at seven-transmembrane receptors
2007 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of Osteoporosis
2010 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Teriparatide [Human PTH(1-34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis
2006
Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline
2012
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation
2009 StandoutNobel
Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective
2012
Explaining Gaps in Readiness for College-Level Math: The Role of High School Courses
2008
The amazing osteocyte
2010 Standout
Interrater reliability: the kappa statistic
2012 Standout
Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)
2008
Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters
2005
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry
2006
The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine
2014
Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis
2007
Works of Gerald Crans being referenced
Effect of High School Course-Taking and Grades on Passing a College Placement Test.
1999
Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial
2006
Anti-vertebral fracture efficacy of raloxifene: a meta-analysis
2005
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial
2003
Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting
2008
Prognostic utility of a semiquantitative spinal deformity index
2005
Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years
2003
Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures
2005
Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women
2003
Association of severe vertebral fractures with reduced quality of life: Reduction in the incidence of severe vertebral fractures by teriparatide
2004
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover
2006
Effects of Raloxifene on Fracture Severity in Postmenopausal Women with Osteoporosis: Results from the MORE Study
2002
Efficacy and Safety of Raloxifene 60 Milligrams/Day in Postmenopausal Asian Women
2003
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
2004
Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk
2004
P2‐476: A Phase 1, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral daily doses of ELND006 in healthy elderly subjects
2011
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
2011
Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma
2017